Matrix Labs partners with Clinton Foundation

Matrix Labs partners with Clinton Foundation

Hyderabad: Drugmaker Matrix Laboratories Ltd on Friday said it has agreed to supply the Clinton Foundation an affordable second-line of anti-retroviral (ARV) drugs for patients with HIV/AIDS who have developed resistance to first-line drugs.

The Hyderabad-based Matrix Labs, a subsidiary of the US drug firm Mylan Inc., said its second-line ARV therapy would cost a patient some $475 for a year now, and $425 in 2010.

Former US president Bill Clinton, who runs the Clinton Foundation, announced two deals on Thursday evening in the US, the other agreement being with Pfizer Inc. for the supply of affordable second-line ARV drugs for patients also suffering from tuberculosis.

Close